Author: Janna Carina Bülhoff
Last saved by: Sascha Buhr

Julio Triana appointed to Board of Management of Bayer AG 
and President of the Consumer Health Division 
Heiko Schipper to leave the company on April 30, 2024

Leverkusen, February 29, 2024 – The Supervisory Board of Bayer AG has appointed Julio Triana (58) to Bayer’s Board of Management effective April 1, 2024. He will become President of the Consumer Health Division effective May 1, 2024, and succeed Heiko Schipper (54), who has asked the Supervisory Board to bring forward the end date of his contract in order to pursue a career opportunity outside of Bayer. Schipper will leave the company effective April 30, 2024.

“We are extremely pleased to have Julio Triana join Bayer’s Board of Management and assume leadership of our Consumer Health business,” said Prof. Dr. Norbert Winkeljohann, Chairman of the Supervisory Board of Bayer AG. “He brings a unique combination of financial, marketing, scientific and analytical skills to business leadership. His three decades of leadership in healthcare across four continents, and his proven track record of sustainably growing businesses make him the ideal leader to expand our portfolio of everyday health solutions and realize its full potential. Julio is known for his collaborative and purpose-driven approach and for building diverse, inclusive and empowered teams and we expect him to be a major force for driving the transformation of Bayer,” said Winkeljohann. “At the same time, we would like to warmly thank Heiko Schipper for his great achievements during the past six years at Bayer. He has successfully led and strategically transformed the Consumer Health Division, bringing it back to the forefront of the industry. We wish him all the very best for the future.”

Julio Triana is currently Head of Commercial Operations Region International for Bayer’s Pharmaceuticals Division, a member of the Division’s Executive Committee as well as the Senior Bayer Representative Japan and President of Bayer Holding, Ltd. Japan. Triana is a very seasoned executive with a dynamic 30-year career in the global healthcare industry. He joined Bayer in 2002, and has held roles of increasing responsibility in Finance, Strategy, Business Development and most recently Commercial Operations, among others. Triana holds an MBA from Universidad Antonio de Nebrija (Madrid, Spain) as well as a Bachelor of Science in Biology from University of Houston (Houston, Texas, USA). He has comprehensive experience in leading and transforming large organizations across multiple functions and in different cultural contexts with a strong track record of successful market expansions, sustainable revenue growth and orchestrating complex integrations. 

Triana is married with one son and in addition to his native country, Colombia, he has lived and worked in Argentina, Brazil, Spain, USA, Switzerland, Germany and Japan. 

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Note:
Print-quality photos can be downloaded from our website at 
www.bayer.com/media/en-us/

Contact for media inquiries:
Diana Scholz, phone +41 79 674 60 23
Email: diana.scholz@bayer.com

Christian Hartel, phone +49 214 30-47686
Email: christian.hartel@bayer.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com 
www.bayer.com/en/investors/ir-team

Follow us on twitter.com/bayer

ds	(2024-0046E)

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.